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Background: Malignant pleural mesothelioma is an aggressive tumor that has a poor prognosis and is resistant to
unimodal approaches. Multimodal treatment has provided encouraging results.
Methods: Phase II, open-label study of the combination of chemotherapy (pemetrexed 500 mg/m2+cisplatin
75 mg/m2 IV every 21 days × 3 cycles), followed by surgery (en-bloc extrapleural pneumonectomy, 3–8 weeks after
chemotherapy) and hemithoracic radiation (total radiation beam 54 Gy, received 4–8 weeks post-surgery). The
primary endpoint was event-free survival, defined as the time from enrollment to time of first observation of
disease progression, death due to any cause, or early treatment discontinuation.
Results: Fifty-four treatment-naïve patients with T1-3 N0-2 malignant pleural mesothelioma were enrolled, 52
(96.3%) completed chemotherapy, 45 (83.3%) underwent surgery, 22 (40.7%) completed the whole treatment
including 90-day post-radiation follow-up. The median event-free survival was 6.9 months (95%CI: 5.0-10.5), median
overall survival was 15.5 months (95%CI 11.0-NA) while median time-to-tumor response was 4.8 months (95%CI:
2.5-8.0). Eighteen (33.3%) and 13 (24.1%) patients were still event-free after 1 and 2 years, respectively. The most
common treatment-emergent adverse events were nausea (63.0%), anemia (51.9%) and hypertension (42.6%).
Following two cardiopulmonary radiation-related deaths the protocol was amended (21 [38.9%] patients were
already enrolled in the study): the total radiation beam was reduced from 54 Gy to 50.4 Gy and a more accurate
selection of patients was recommended.
Conclusions: The combination of pemetrexed plus cisplatin followed by surgery and hemithoracic radiation is
feasible and has a manageable toxicity profile in carefully selected patients. It may be worthy of further
investigation.
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Malignant pleural mesothelioma (MPM) is an aggressive
tumor originating from the superficial serosal cells of
pleural cavities that has long been considered rare. In-
deed, its incidence has considerably increased over the
past two decades in industrialized countries on account
of the widespread use of asbestos, the main carcinogen
involved in its pathogenesis. The incidence of malignant
mesothelioma is currently reported to range from 7 to
40 cases per million people, but it is believed that it will
increase in the next 10 to 15 years [1].
MPM rapidly spreads to adjacent structures of the
thoracic cavity. This explains why the majority of
patients present with locally advanced or metastatic dis-
ease: 48% are in stage III and 40% are in stage IV [2,3].
The prognosis of MPM is poor. The median overall
survival (OS) from diagnosis is 12 months, ranging from
8 months in stage IV patients to 40 months in stage I
patients [4].
At present, an optimal therapy for MPM has not been
established. In the recent Mesothelioma and Radical
Surgery (MARS) study, in which patients with patho-
logically confirmed mesothelioma were randomized to
extrapleural pneumonectomy (EPP) or no EPP within
the context of trimodal therapy, the surgery option was
reported to offer no benefit and possibly harms patients
[5]. Previous studies showed that MPM is refractory to a
series of single modality regimens based on chemother-
apy, surgery, or radiotherapy [6]. An attempt to curative
surgery, consisting of EPP, is feasible in no more than
5% of subjects [2]. Single-agent chemotherapy provides
poor response rates (<20%) and no improvement in me-
dian survival [4]. The only advancement with a single
modality is the identification of cisplatin as the best
anticancer agent for MPM in a meta-analysis of studies
published between 1965 and 2001. The combination of
cisplatin and pemetrexed has shown to improve the ob-
jective response rate and to prolong median overall sur-
vival of patients with MPM versus cisplatin alone (41%
vs 16.7%, 12.1 vs 9.3 months) within the context of a
prospective, randomized, phase III clinical trial [7,8].
Radiotherapy with curative intent is usually not recom-
mended, as target volumes exceed normal tissue toler-
ance limits [9]. Even though the modern Intensity
Modulated Radiation Therapy (IMRT) technique seems
to provide additional treatment options, it still requires
further investigation [4,7].
In view of the resistance of MPM to single modality
approaches, multimodal therapeutic strategies have been
proposed. Studies assessing trimodal treatment (induc-
tion chemotherapy, followed by EPP and post-operative
radiotherapy) have provided encouraging results [10,11].
The present trial, whose primary endpoint is event-
free survival (EFS), was designed to test the feasibility,and assess efficacy and safety of the combined modality
approach (induction chemotherapy followed by EPP and
hemithoracic radiation) in patients with MPM with clin-
ical stage I, II, or III (T1-3 N0-2).
Methods
The present clinical trial (clinicaltrial.com ID #NCT00
087698) aimed to assess the efficacy of the trimodality ap-
proach (chemotherapy, surgery and radiation) for the treat-
ment of stage I-III MPM. A CONSORT (consolidated
standard in reporting trials)-like diagram, including study
design and patients disposition is presented in Figure 1.
The study was approved by local ethics committees
(Comitato Etico degli Istituti Fisioterapici Ospitalieri
(IRCCS) di Roma, Rome, Italy; Comitato Etico Istituto
Europeo di Oncologia, Milan, Italy; Comitato Etico Per La
Sperimentazione Azienda Ospedaliera of Padua, Padua,
Italy; Comitato Etico ULSS 12 Veneziana, Venice, Italy) and
was conducted in accordance with the Declaration of Hel-
sinki on ethical principles for medical research involving
human subjects.
Objectives of the study
The primary efficacy objective of this study was to assess
the EFS, defined as the time from enrollment to the first
observation of disease progression, death due to any cause,
or early treatment discontinuation. EFS was censored at the
date of the last follow-up visit for patients who did not dis-
continue early, who were still alive and had not progressed.
Secondary efficacy objectives were to assess: 1- and 2-
year EFS rates; progression-free survival (PFS), defined
as the time from study enrollment to the first date of
disease progression or death as a result of any cause
(PFS was censored at the date of the last follow-up visit
for patients who were still alive and who have not pro-
gressed); OS, defined as the time from study enrollment
to time of death from any cause (OS was censored at the
date of last follow-up for patients who were still alive);
and time to tumor response (TTR), defined as the time
from study enrollment to the first observation of an ob-
jective tumor response.
Eligibility criteria
Patients who were at least 18 years old, had signed
informed consent and met all criteria listed in Table 1
were enrolled in the study.
Treatment plan
Chemotherapy
Pemetrexed (500 mg/m2 intravenous [IV] infusion) fol-
lowed by cisplatin (75 mg/m2 IV infusion) were adminis-
tered to patients on Day 1 of a 21-day cycle for a total of
three cycles. Supportive therapy of folic acid, vitamin B12
and dexamethasone (4 mg bid per os) were given.
Figure 1 Study design and patients disposition adopted in this study. Study design highlights the trimodality therapy adopted: patients
disposition is provided for patients enrolled before the protocol amendment (PA) as well as for those enrolled after PA and overall. Trimodality
therapy was considered completed for those patients who received ≥28 doses of radiotherapy (RT) while the study was considered completed
for those subjects completing RT and the 90-day post-radiation follow-up. pts = patients; MPM = malignant pleural mesothelioma;
HTR = hemithoracic radiation; EPP = extrapleural pneumonectomy; BA = before amendment; AA = post amendment.
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EPP was performed 3 to 8 weeks after the last dose
of chemotherapy in eligible patients to achieve the
complete resection of the gross residual tumor. EPP
involved en-bloc resection of the pleura, lung, dia-
phragm, and ipsilateral half of the pericardium. Patients
were eligible for surgery unless objective evidence of dis-
ease progression was present or deterioration of func-
tional status occurred.
Radiation
Radiation was given to patients starting from 4 to
8 weeks after EPP (an extension to 12 weeks was pos-
sible as per study protocol). The clinical target volume
(CTV) was contoured on each patient after a radiationoncologist and thoracic surgeon had discussed it. A total
of 54 Gy radiation beam (30 × 1.8 Gy fractions) was
administered to patients. Once patients received a total
radiation of 40 Gy a non-enhanced CT scan was performed
for safety evaluation. Due to two cardiopulmonary-related
deaths that occurred earlier in the study, the study protocol
was amended reducing the total radiation beam to 50.4 Gy
(28 × 1.8 Gy fractions). Additional cardiopulmonary and re-
spiratory function tests were also performed (Table 2).Statistics
Determination of sample size
Based on the assumption of a 1-year EFS rate of about
30%, 53 patients were planned to be enrolled in the
Table 1 Eligibility criteria of this study
Eligibility
Criteria
Clinical stage I, II or III (M0; N0-2; T1-3) pleural mesothelioma
Performance status 0 to 1on the ECOGa performance status schedule
No previous surgical resection of mesothelioma
No previous radiation therapy
Estimated life expectancy of at least 12 weeks
Adequate cardiac function
Must be judged suitable to the therapy by medical oncologist and thoracic surgeon.
Pulmonary function tests: FEV1b >0.8, DLCOc >35% of predicted postoperative FEV1 (ppoFEV1)
ABGd Predicted postoperative pCO2 <50.
Adequate bone marrow reserve:
• absolute neutrophil (segmented and bands) count (ANC) ≥1.5 × 109/L,
• Platelets ≥100 × 109/L, and hemoglobin ≥9 g/dL.
Hepatic: bilirubin ≤1.5 times the upper limit of normal
(× ULN), alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤3.0 × ULN.
Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy
test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose
of study drug.
Geographical condition must not hamper the compliance with the study protocol and follow-up schedule.
a Eastern Cooperative Oncology Group;b Forced Expiratory Volume;c Diffusing Capacity of the Lung for Carbon monoxide;d Arterial Blood Gas.
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about ±12% around the 1-year EFS rate.Efficacy analysis
Efficacy analyses were performed on the full analysis set
(FAS), defined as all patients with histological or cytological
diagnosis of MPM; no prior or concurrent systemic chemo-
therapy, immunotherapy, or biological therapy; presence of
measurable or evaluable disease (for clinical response); and
treated with at least one dose of pemetrexed/cisplatin. For
all time-to-event variables, Kaplan-Meier curves were gen-




FEV 1 >2 L, or >35% of predicted postoperative (ppoFEV1); if < 2 L,
ppoFEV1 must be at least 35% based on the following formul
using the quantitative V/Q scan: Predicted post-resection
FEV1 = FEV1 x % perfusion to uninvolved lung from quantitat
lung V/Q scan report.
DLCO > 35% of ppoFEV1




The patient's cardiac function and presence or absence of cor
artery disease or valvular heart disease should be assessed by
the following tests:
• Radionuclide stress test: preferred
• Exercise stress test to maximal exercise level
• Stress echocardiogramtime-to-event rates) were calculated and 95% CIs around
the estimates were provided.Safety analysis
Safety analyses were performed on the safety population,
defined as all patients who received at least one dose of
pemetrexed/cisplatin. Safety analyses included analyses
of vital signs, laboratory and non-laboratory variables at
each visit, and the changes from baseline. Shift tables
showing laboratory test values classified as below nor-
mal, normal, and above normal, based on reference






predicted postoperative pCO2 < 50
onary
one of
The patient's cardiac function and presence or absence of
coronary artery disease or valvular heart disease should be
assessed by the following tests:
• Echocardiogram (mandatory): Ventricular Ejection Fraction 3 45%
• Electrocardiogram (mandatory)
• Radionuclide stress test (optional)
• Exercise stress test to maximal exercise level (optional)
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The study was conducted at four centers in Italy from
June 2005 to February 2010. A total of 56 patients were
screened for the study and 54 were enrolled.
Patient characteristics
The patients were mostly men (n=47, 87%) and had a
median age of 63.0 years (range: 39–75 years) (Table 3).
Twelve patients (22.2%) were in clinical stage I (T1,
N0, M0), 9 (16.7%) were in clinical stage II (T2, N0, M0)
and 33 (61.1%) were in clinical stage III (T1-3, N1-2,
M0). Twenty-one patients (38.9%) were enrolled before
the protocol amendment, implemented after two cardio-
pulmonary failure-related deaths, reducing the dose of




Of the 54 patients enrolled, 52 (96.3%) patients com-
pleted pre-operative chemotherapy; one patient received
only 2 cycles because of lack of efficacy and another
received only one cycle because he experienced an acute
myocardial infarction.
The median relative dose intensity of pemetrexed was
100% (range 33%-113%), that of cisplatin was 100.3%
(range 33%-144%). Out of 159 cycles, 8 cycles of peme-
trexed (5.0%) were delayed, one (0.6%) was reduced, and
one (0.6%) was reduced and delayed, whereas 7 cycles ofTable 3 Characteristics of patients enrolled before and
after the study protocol amendment
Before PAa After PA All
N Gender, n (%) 21 33 54
Male 17 (81.0) 30 (90.9) 47 (87.0)










Caucasian 21 (100.0) 33 (100.0) 54 (100.0)
Clinical Staging, n (%)
I (T1,N0,M0) 1 (4.8) 11 (33.3) 12 (22.2)
II (T2,N0,M0) 2 (9.5) 7 (21.2) 9 (16.7)
III (T3,N1-
2 M0)
17 (81.0) 16 (48.5) 33 (61.1)
Histology,n (%)
Epithelial 18 (85.7) 30 (90.9) 48 (88.9)
Biphasic 2 (9.5) 1 (3.0) 3 (5.6)
Desmoplastic 1 (4.8) 2 (6.1) 3 (5.6)
a Protocol Amendment
Data are presented stratified by time of enrollment in this study with respect
to the protocol amendment and are expressed as number of patients
(percentage) except for age, expressed as mean (SD).cisplatin (4.4%) were delayed, one (0.6%) was reduced,
and two (1.3%) were delayed and reduced.
Surgery
Of the 54 patients enrolled, 9 patients dropped out of
the study before surgery (6 due to lack of efficacy, 2 due
to death and one patient was found to have invasion of
the esophagus) while 45 (83.3%) underwent surgery. Of
these, 9 patients were in clinical stage I, 8 were in clin-
ical stage II and 34 were in clinical stage III. Among the
patients who underwent surgery, 41 (91.1%) received
EPP, while 4 (8.9%) did not. En- bloc EPP was performed
in 36 patients (80.0%), non-“en- bloc” EPP in 5 patients
(11.1%). Resection of the pericardium was performed in
38 patients (84.4%), resection of the diaphragm in 40
(88.9%) patients. A diaphragmatic prosthesis was inserted
during 34 procedures (75.6%), a pericardial prosthesis in
33 patients (73.3%). A total of 2 patients (4.4%) died within
30 days of surgery.
Radiotherapy
Of the 45 patients who underwent surgery, 32 received
radiotherapy (59.3% of total enrolled patients) while 13
(24.1%) did not (see Figure 1 for details). The median
number of fractions received was 28 (range 12–30) and
the median total dose received was 50.4 Gy (range: 21.6
to 54.0 Gy).
Twenty-two patients (40.7%) completed the trimodal-
ity treatment and the 90-day post radiation follow-up
(Figure 1). Out of the remaining 32 patients, 16 were
removed from the study earlier because of inefficacy
(29.6%), mainly after chemotherapy or after surgery; 11
(20.4%) died, two (3.7%) violated the protocol, one
experienced an unacceptable adverse event, one decided
to withdraw, and one was removed from the study by
the investigator. Out of the 11 deaths, five were consid-
ered to be unrelated to the study (diagnosis: broncho-
pneumonia, septic shock, suspected heart attack,
underlying disease, suicide), two were due to study drug
toxicity (cardiopulmonary failures), four were procedure
related (1 empyema, 1 cardiac arrest, and 2 sepsis).
Efficacy
The median EFS was 6.9 months (95%CI: 5.0- 10.5)
(Figure 2A). A total of 18 (33.3%; 95%CI: 21.1- 47.5)
and 13 (24.1%, 95%CI: 13.7- 36.0) patients were still
event-free after 1 and 2 years, respectively. The median
PFS was 8.6 months (95%CI: 6.3, 14.4 months) (Figure 2B);
the one-year PFS rate was 40.7% (95%CI: 27.7-53.4); the
2-year PFS rate was 31.5% (95%CI: 19.7-43.9). The median
OS was 15.5 months (95%CI: 11.0-NA) (Figure 2C). The
1-year OS rate was 59.2% (95%CI: 44.9- 70.9). Median TTR
was 4.8 months (95%CI: 2.5-8.0) (Figure 2D). Overall, 31
patients had progression of disease. Of these, 10 patients
Figure 2 Efficacy variables of this study. Kaplan-Meier plots for efficacy variables analyzed for this study are presented: Median EFS (panel A),
Median PFS (panel B), Median OS (panel C) and median TTR (panel D). Results are expressed in months. EFS= event-free survival; PFS=
progression-free survival; OS= overall survival; TTR= time to tumor response.
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sion: 6 local, 4 distant), while 21 had progression of disease
during the follow-up period (site of progression: 5 local,
1 contralateral intrathoracic, 15 distant). Following two
cardiopulmonary-related deaths, the study protocol was
amended by reducing the total radiation dose administered
to patients (see Methods section) and including additional
cardiopulmonary and respiratory function tests (Table 2),
which led to a more careful selection of patients being
carried out.Safety
No important changes in vital signs, body weight, and
Eastern Cooperative Oncology Group (ECOG) perform-
ance status were recorded.
Nearly all patients experienced at least one adverse
event (AE) (n=53, 98.1%). The most common treatment-
emergent AEs were nausea (63.0%), anemia (51.9%) and
hypertension (42.6%). The total number of deaths
recorded was 32 patients (59.3%). Of these, 11 patients
died during the study (causes of death were: 1 broncop-
neumonia, 1 septic shock, 1 empyema, 1 suspect heart
attack, 1 cardiac failure, 1 respiratory failure, 1 cardiac
arrest, 2 sepsis, 1 suicide and 1 death for unknown
causes) while 21 died during the follow-up period
(causes of death were: 19 progression of disease [10 dis-
tant vs 9 local], 1 sepsis, 1 unknown).Twenty-six patients (48.1%) required a blood transfu-
sion. Thirty-six (66.7%) patients experienced at least one
grade 3/4 toxicity and two patients died because of car-
diopulmonary failure. Forty-two patients (77.8%) experi-
enced at least one AE related to chemotherapy, which in
5 patients (9.3%) were serious. The corresponding rates
for radiotherapy were 48.1% and 13%, respectively. The
number of episodes of grade 3/4 toxicities related to
treatment were: lymphopenia (n=3), neutropenia (n=3),
dyspnea (n=3, all serious), anemia (n=2, 1 serious), heart
failure (n=2, both serious), respiratory failure (n=2, both
serious), acute cor pulmonale, myocardial infarction,
pericardial effusion, emphysema, acute respiratory dis-
tress syndrome, pneumonia, bronchial fistula, subcuta-
neous emphysema (n=1 each, all serious), dysphagia (n=1),
mucosal inflammation (n=1), hyponatremia (n=1), and scar
pain (n=1). No important qualitative differences were
recorded after the implementation of protocol amendment.
Discussion
Malignant pleural mesothelioma is an aggressive tumor
refractory to single regimens based on chemotherapy,
surgery, or radiation [5]. Although IMRT technique
seems to provide an additional treatment option (still re-
quiring further investigations) clinical studies provided
encouraging results on combined modality approach
treatments [10,11]. The present study was designed to
test the feasibility and assess the efficacy and safety of
Table 4 Summary results for efficacy variables
Before PAa After PA Overall
EFSb
Median 6.3 (3.3-10.5) 8.1 (4.1 - 19.7) 6.9 (5.0-10.5)
1-year Rate 23.8 (8.2-47.2) 39.4 (22.9-57.9) 33.3 (21.1-47.5)
2-year Rate 14.3 (3.6-32.1) 30.3 (15.9-46.1) 24.1 (13.7-36.0)
PFSc
Median 6.6 (5.0-11.0) 11.9 (6.9-26.9) 8.6 (6.3-14.4)
1-year Rate 28.6 (11.7-48.2) 48.5 (30.8-64.1) 40.7 (27.7-53.4)
2-year Rate 19.1 (5.9-37.7) 39.4 (23.1-55.4) 31.5 (19.7-43.9)
OSd
Median 12.6 (6.9-21.1) NA 15.5 (11.0-NA)
TTRe
Median 2.8 (1.4-5.1) 7.6 (4.1-8.9) 4.8 (2.5-8.0)
a Protocol Amendment; b Event-free Survival; c Progression-free Survival; d
Overall Survival; e Time to Tumor Response.
Overall results are presented as well as results stratified by time of enrollment
in the study with respect to the protocol amendment. Results are expressed in
months (95% CI) for median variables and as percentage (95% CI) for 1- and
2-year rates.
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by EPP and hemithoracic radiation.
For the primary endpoint of EFS assessed for the
study, the median EFS was 6.9 months (95% CI: 5.0 to
10.5), while the 1- and 2-year EFS rates were, respect-
ively, 33.3% (95% CI: 21.1- 47.5) and 24.1% (95% CI: 13.7-
36.0). Considering that the sample size determination was
based on the assumption that the expected 1-year EFS
rate of about 30% (with a 95% CI of about ±12%), the
1-year EFS rate observed in the present study aligned
with the initial assumption. Therefore, these results in-
dicate that the adopted multimodality approach is
feasible.
Although the 1-year EFS rate observed based on all
the enrolled patients in the present study aligns with
what is expected, it is possible that the subgroup of
patients who completed all the three treatments have
higher survival benefits. Indeed, a total of 22 (40.7%) of
the 54 patients completed all the study treatments in-
cluding the 90-day post-radiation follow-up. However,
given the change in patients’ selection criteria following
the protocol amendment (as described in the Methods
section), it is important to consider mainly results based
on all enrolled patients rather than the subgroup of
patients in the present study.
Generally, results obtained for efficacy endpoints other
than EFS, were lower than those reported by Van Schil
et al.[12] in the EORTC study, a clinical trial with similar
study design but different primary objective. The median
PFS and 1-year PFS rate were 8.6 months (95% CI:
6.3- 14.4) and 40.7% (95% CI: 27.7-53.4), respectively,
compared to 13.9 months (95% CI: 10.9-17.2) and 54.4%
(95% CI: 40.7-66.2), respectively, obtained in the EORTC
trial [12]. The median OS was 15.5 months (95% CI:
11.0-NA) compared to 18.4 months (95% CI: 15.6-32.9)
in the EORTC [12]. The same outcome in the MARS
trial was of 14.4 months (95%CI: 5.3-18.7) for patients
randomized to EPP and of 19.5 months (95%CI: 13.4-not
reached) for patients randomized to no EPP. [5]. Fur-
thermore, the efficacy outcomes of the present study
were less favorable as compared with those obtained in
the SAKK and USA phase II trials [9,10].
However, we have to consider that following two
cardio-pulmonary related deaths the study protocol was
amended and the total radiation dose was reduced from
54 Gy to 50.4 Gy. It is noteworthy that the outcomes of
efficacy endpoints, including the primary endpoint of
EFS, did not worsen but instead seem to benefit from
the changes introduced by the protocol amendment.
Even though no claim of statistical significance can be
made against the variation of efficacy variables when
measured before or after the amendments, these findings
seem to suggest that the reduced post-surgery radiation
dose may lead to increased OS, EFS, PFS and TTR(Table 4) but this hypothesis needs to be confirmed in a
further study. With regard to the safety profile, the
adopted combination of pemetrexed plus cisplatin fol-
lowed by EPP and hemithoracic radiation did not result
in abnormal values either for cardiac or pulmonary func-
tion tests at baseline and after surgery. These results,
taken together with no clinically relevant changes in vital
signs, no substantial changes in the blood chemistry
from baseline and generally acceptable decreases in cer-
tain hematologic values (hemoglobin, red blood cells
[RBCs] count, white blood cells [WBCs] count, platelets
and neutrophils), indicate a manageable toxicity profile
following the reduced radiation dose.
Unlike the MARS trial [5] that was designed to assess
the clinical outcomes of patients who were randomly
assigned to EPP or no EPP in the context of trimodal
therapy, the present non-randomized study, that was
disegned to to test the feasibility and assess the efficacy
and safety of the combination of pemetrexed and cis-
platin followed by EPP and hemithoracic radiation,
recruited also patients of worst outcome (i.e. desmoplas-
tic MPM histotype – see also Table 3). However, the low
number of patients belonging to this subpopulation may
not have had an impact on the final results. Moreover,
the MARS trial allowed three different regimens of
chemotherapy at physician discretion [5] while the
present trial considered a pemetrexed-based regimen as
the only chemotherapy option.
Based on median survival (14.4 months (95%CI: 5.3-18.7)
for patients randomized to EPP and of 19.5 months (95%
CI: 13.4-not reached) for patients randomized to no EPP)
and mortality (18%) outcomes recorded in the MARS trial,
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therapy offers no benefit and possibly harms patients. As
suggested by Weder et al. [13] this conclusion is not sup-
ported by data and possibly might move clinical research
for mesothelioma in the wrong direction [13]. Provided that
superiority of pleurectomy vs EPP has not been proved yet,
we would like to strongly remark that the present study
was not designed to compare different surgical strategies,
therefore no conclusion nor speculation about pleurectomy
vs EPP can be done. On the other hand, the low rate of
completion (40.7%) recorded in this study, highlight the
need for a careful patient selection and eventually, for a tai-
lored surgical and medical approach.
The present study has limitations that were mainly
introduced by the protocol amendment even though not
predictable in advance. Because improvement of efficacy
outcomes was not expected a priori, the sample size was
not recalculated to allow comparison of data stratified
by time of enrollment with respect to the protocol
amendment. Thus, the analyses were limited to the over-
all efficacy outcomes. A possible additional bias may be
that, after the protocol amendment, patients were not
equally enrolled across all the participant study centers.
Conclusions
This study provides further evidence that, under a care-
ful patient selection, the combination of pemetrexed
plus cisplatin followed by EPP and hemithoracic radi-
ation is feasible, with a manageable toxicity profile, and
may be further exploited.
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